StockData
Interpace Biosciences, Inc. logo

Interpace Biosciences, Inc. (IDXG) stock

IDXGOTCSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 10/30
$5.00−0.15 (-2.91%)

Close on Oct 19, 2026Market cap $138.57MP/E 5.6Yield –

Earnings

Interpace Biosciences's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Jan 19, 2027
Q4 FY2026 · estimated, before the open
Revenue, Q2 FY2026
$9.13M
-0.7% on a year earlier
EPS, Q2 FY2026
$0.01
-$0.14 a year earlier
Latest guidance
Issued
Oct 15, 2026 · 1 item

Quarterly results

Revenue and earnings per share from each of Interpace Biosciences's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q4 FY2026ended Dec 31, 2026Jan 19, 2027Expected––––
Q3 FY2026ended Sep 30, 2026Oct 15, 2026before the open–––Release
Q2 FY2026ended Jun 30, 2026Aug 12, 2026after the close$9.13M-0.7%$0.01Release
Q1 FY2026ended Mar 31, 2026May 14, 2026after the close$9.00M-21.7%$0.03Release
Q4 FY2025ended Dec 31, 2025Jan 20, 2026before the open–––Release
Q3 FY2025ended Sep 30, 2025Nov 12, 2025after the close$8.80M-28.4%$0.03Release
Q2 FY2025ended Jun 30, 2025Aug 8, 2025after the close$9.20M-23.3%-$0.14Release
Q1 FY2025ended Mar 31, 2025May 8, 2025after the close$11.50M–$0.06Release
Q3 FY2024ended Sep 30, 2024Nov 6, 2024after the close$12.30M–$0.29Release
Q2 FY2024ended Jun 30, 2024Aug 2, 2024after the close$12.00M–$0.46Release
Q1 FY2024ended Mar 31, 2024May 9, 2024after the close–––Release
Q4 FY2023ended Dec 31, 2023Mar 13, 2024after the close–––Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

Interpace Biosciences's latest outlook for periods it has not reported yet, compared with what it said before

MetricPeriodGuidanceBeforeChangeGiven
revenueQ3 FY2026$10.10M – $10.40M–NewOct 15, 2026
full-year 2026 revenueFY2026$40.00M–NewJan 20, 2026
year-over-year thyroid revenue growthFY2026+16%–NewMay 14, 2026
growth in thyroid testing revenueFY2026+16%–NewJan 20, 2026
thyroid revenue growthFY2026+16%–ReaffirmedApr 1, 2026

Guidance history

Every forecast Interpace Biosciences put in an earnings release, newest first

GivenMetricPeriodGuidanceChange
Oct 15, 2026revenueQ3 FY2026$10.10M – $10.40MNew
May 14, 2026year-over-year thyroid revenue growthFY2026+16%New
Apr 1, 2026thyroid revenue growthFY2026+16%Reaffirmed
Jan 20, 2026growth in thyroid testing revenueFY2026+16%New
Jan 20, 2026full-year 2026 revenueFY2026$40.00MNew
May 8, 2025revenue guidanceFY2025$38.00MNew

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.

Press releases

Releases Interpace Biosciences filed with the SEC as exhibits to Form 8-K or 6-K

  1. Results
  2. Results
  3. Update
  4. Results
  5. Results
  6. Results
  7. Results
  8. News
  9. Results
  10. Results
  11. Results
  12. News
  13. News
  14. Results
  15. Update

See a number that looks wrong?